Findings

What do systematic reviews say?

4,736 questions · 15,265 findings · 1,163 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,871 · 25.4%GRADE not reported 810 · 5.3%Very low 4,242 · 27.8%Low 3,879 · 25.4%Moderate 1,999 · 13.1%High 464 · 3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Recombinant human C1 esterase inhibitor vs placebo or active control

Adverse events(during · children or adults with Types I or II HAE

Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.39 [0.71, 2.7]
1 study · 29 participants
Low

Lanadelumab vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lanadelumab vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 83 participants
Low

Lanadelumab vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lanadelumab vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.88 [0.08, 10.39]
2 studies · 162 participants
Low

Lanadelumab vs placebo or active control

Differences in quality of life ( · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Low

Lanadelumab vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Lanadelumab vs placebo or active control

Adverse events(during · children or adults with Types I or II HAE

Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.07 [0.77, 1.47]
2 studies · 158 participants
Low

Avoralstat vs placebo

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 93 participants
Moderate

Avoralstat vs placebo

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avoralstat vs placebo

Adverse events (during · children or adults with Types I or II HAE

Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.85 [0.62, 1.16]
1 study · 24 participants
Low

Berotralstat vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

Berotralstat showed no clear difference in risk of HAE attacks (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.63 [0.39, 1]
1 study · 37 participants
Low

Berotralstat vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Low

Intervention not reported

Total studies: 56 Total participants: 9419 · older adults (> 60 years of age) with intracapsular hip fractures; most fractures in the included studies were displaced

1 finding from 1 review

Surgical interventions for treating intracapsular hip fractures in older adults: a network meta‐analysis 2022 · Cochrane Headline outcomes only
no estimate extracted
56 participants
GRADE not reported

Intervention not reported

Pins (No direct evidence, indirect evidence only) · older adults (> 60 years of age) with intracapsular hip fractures; most fractures in the included studies were displaced

It is very uncertain whether the intervention changes pins (No direct evidence, indirect evidence only) (very low certainty).

1 finding from 1 review

Surgical interventions for treating intracapsular hip fractures in older adults: a network meta‐analysis 2022 · Cochrane Headline outcomes only
RR 1.03 [0.78, 1.37]
Studies not reported
Very low

Intervention not reported

Screws (3 RCTs; 152 participants)a · older adults (> 60 years of age) with intracapsular hip fractures; most fractures in the included studies were displaced

It is very uncertain whether the intervention changes screws (3 RCTs; 152 participants)a (very low certainty).

1 finding from 1 review

Surgical interventions for treating intracapsular hip fractures in older adults: a network meta‐analysis 2022 · Cochrane Headline outcomes only
RR 1.09 [0.9, 1.33]
3 studies · 152 participants
Very low

Intervention not reported

Non‐operative treatment (No direct evidence, indirect evidence only) · older adults (> 60 years of age) with intracapsular hip fractures; most fractures in the included studies were displaced

It is very uncertain whether the intervention changes non‐operative treatment (No direct evidence, indirect evidence only) (very low certainty).

1 finding from 1 review

Surgical interventions for treating intracapsular hip fractures in older adults: a network meta‐analysis 2022 · Cochrane Headline outcomes only
RR 1.1 [0.59, 2.07]
Studies not reported
Very low

Intervention not reported

Cemented modern unipolar hemiarthroplasty · older adults (> 60 years of age) with intracapsular hip fractures; most fractures in the included studies were displaced

The review found no eligible studies for this question.

1 finding from 1 review

Surgical interventions for treating intracapsular hip fractures in older adults: a network meta‐analysis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 13 Total participants: 2744 · older adults (> 60 years of age) with intracapsular hip fractures; most fractures in the included studies were displaced

1 finding from 1 review

Surgical interventions for treating intracapsular hip fractures in older adults: a network meta‐analysis 2022 · Cochrane Headline outcomes only
no estimate extracted
13 participants
GRADE not reported

Intervention not reported

Dynamic fixed angle plate (No direct evidence, indirect evidence only) · older adults (> 60 years of age) with intracapsular hip fractures; most fractures in the included studies were displaced

1 finding from 1 review

Surgical interventions for treating intracapsular hip fractures in older adults: a network meta‐analysis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low